Parainfluenza virus type 3 infectious disease
MONDO:0042974Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (HPIV) that cause a variety of respiratory illnesses. Symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. Symptoms may include fever, runny nose, and cough. HPIV-3 can also cause bronchiolitis, bronchitis, and pneumonia. Infants and young children are particularly susceptible to HPIV-3 infections, though older adults and those with a weakened immune system are also at risk for complications. HPIVs are usually spread from an infected person to others through coughing, sneezing, and/or touching. There is currently no vaccine to protect against parainfluenza virus infections. Most HPIV infections resolve on their own and do not require special treatment, though medical intervention may be necessary for severe breathing problems. Most adults have antibodies against parainfluenza but can get repeat infections.
Also known as: human respirovirus 3 caused disease or disorder, human respirovirus 3 disease or disorder, human respirovirus 3 infectious disease, infection due to human parainfluenza virus 3, PIV3, human parainfluenza virus type 3, infection caused by human parainfluenza virus 3, infection caused by parainfluenza virus 3
7 clinical trials for this condition and its sub-types, 4 tagged with Parainfluenza virus type 3 infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Parainfluenza virus type 3 infectious disease
-
Nasal spray vaccine aims to protect kids from two breathing viruses
Vaccine CompletedThis study tested two experimental nasal spray vaccines in 24 children aged 2 to 5 years. The vaccines target two viruses that can cause breathing problems: human metapneumovirus (HMPV) and parainfluenza virus type 3 (HPIV3). The main goal was to see if the vaccines are safe and …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
One shot, three viruses? new vaccine trial targets RSV, hMPV, and PIV3 in seniors
Vaccine CompletedThis Phase 1 study tests a new vaccine that aims to protect against three respiratory viruses at once: RSV, hMPV, and PIV3. The trial involves 390 adults aged 60 and older and will check if the vaccine is safe and helps the body produce antibodies. Different combinations and dose…
Phase 1 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New combo vaccine targets flu, RSV, and more in early trial
Vaccine CompletedThis early-stage study tested the safety and immune response of new vaccines that combine protection against flu, RSV, hMPV, and PIV3 in healthy adults aged 18 to 49. Participants received a single shot of one of several vaccine formulas. The goal was to see if these combination …
Phase 1 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 08:11 UTC